FAAH-IN-2
Based on 1 publication(s) in Google Scholar
FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is an inhibitor of FAAH. FAAH-IN-2 is a metabolite of Gefitinib (HY-50895).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.21%
- CAS 番号: 184475-71-6
- 分子式: C15H11ClFN3O2
- 分子量:319.72
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
MedChemExpress(MCE)の使用を引用している文献 FAAH-IN-2
MoreEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
化学情報
-
CAS 番号 184475-71-6
-
性状 Solid
-
分子量 319.72
-
分子式 C15H11ClFN3O2
-
Color Off-white to yellow
-
SMILES
OC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1OC
-
別名
O-Desmorpholinopropyl Gefitinib
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Differ
FAAH served a key membrane-anchoring and stabilizing role for NLRP3 protein independently of the endocannabinoid system. [Abstract]2023 Jan;30(1):168-183. PMID: 36104448
溶剤 & 溶解度
DMSO : 20.83 mg/mL (65.15 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (317 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Olivier Dasse, et al. Carbamates therapeutic release agents as amidase inhibitors. WO/2008/100977A2.
[2]. Zhu Y, et al. FAAH served a key membrane-anchoring and stabilizing role for NLRP3 protein independently of the endocannabinoid system. Cell Death Differ. 2023 Jan;30(1):168-183. [Content Brief]
[3]. Kumawat S, et al. Dearomative Difluoromethylation of N-Heterocycles and Pharmaceuticals with Bromo(difluoro)acetic Acid. J Org Chem. 2025 Jul 18;90(28):9826-9844. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1277 mL | 15.6387 mL | 31.2774 mL | 78.1934 mL |
| 5 mM | 0.6255 mL | 3.1277 mL | 6.2555 mL | 15.6387 mL | |
| 10 mM | 0.3128 mL | 1.5639 mL | 3.1277 mL | 7.8193 mL | |
| 15 mM | 0.2085 mL | 1.0426 mL | 2.0852 mL | 5.2129 mL | |
| 20 mM | 0.1564 mL | 0.7819 mL | 1.5639 mL | 3.9097 mL | |
| 25 mM | 0.1251 mL | 0.6255 mL | 1.2511 mL | 3.1277 mL | |
| 30 mM | 0.1043 mL | 0.5213 mL | 1.0426 mL | 2.6064 mL | |
| 40 mM | 0.0782 mL | 0.3910 mL | 0.7819 mL | 1.9548 mL | |
| 50 mM | 0.0626 mL | 0.3128 mL | 0.6255 mL | 1.5639 mL | |
| 60 mM | 0.0521 mL | 0.2606 mL | 0.5213 mL | 1.3032 mL |